Table 3 Relative risk associated with the use of progestagens according to duration and recency of use, compared with never use (n=73 664). E3N cohort study (1990–2002)

From: Oral progestagens before menopause and breast cancer risk

 

Duration of use (years)

 

<4.5

⩾4.5

Recency of use

[PY; cases]

RR a

95% CI

[PY; cases]

RR a

95% CI

Current use

[58 751;193]

1.09

0.92–1.29

[9 946;42]

1.44

1.03–2.00

Past use

[132 341;525]

0.97

0.87–1.07

[23 193;120]

1.06

0.88–1.27

Trend (per year since last use)

 

0.99

0.98–1.01

 

0.97

0.95–1.01

  1. aAdjusted for the same covariates as in Table 2.
Back to article page